Actively Recruiting

Age: 18Years - 80Years
All Genders
NCT06559761

Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research

Led by Chinese PLA General Hospital · Updated on 2024-08-19

500

Participants Needed

1

Research Sites

365 weeks

Total Duration

On this page

Sponsors

C

Chinese PLA General Hospital

Lead Sponsor

T

The First Hospital of Jilin University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Hepatocellular carcinoma (HCC) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. Currently, there is a lack of non-invasive and simple indicators to predict the prognosis of HCC patients and assist clinical decision-making. The identification of HCC macroscopic or histopathological classification requires large pathological specimens obtained through surgical resection, but only about 20% of patients are eligible for surgical treatment. Moreover, most liver cancer diagnoses can be confirmed by imaging examinations without relying on pathological results. For patients who have not undergone surgical resection, the lack of histopathological information during treatment means that there is no basis for judging tumor proliferation and obtaining rich prognostic information. Therefore, evaluating the invasion and proliferation ability of HCC based on macroscopic imaging assessment has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. Ultrasound and MRI are ideal entry points as first-line imaging methods for liver cancer diagnosis. This study aims to evaluate HCC macroscopic or histopathological classification based on multimodal imaging (ultrasound, CT, MRI), thereby assessing its invasion and proliferation ability which has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. By analyzing macroscopic image features we aim to explore their cross-scale correlations with HCC macroscopic classification,histopathological classification,and gene molecular typing.

CONDITIONS

Official Title

Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathological diagnosis of hepatocellular carcinoma according to WHO classification
  • Initial treatment is curative-intent hepatectomy
  • No evidence of major vascular or hepatic portal invasion, extrahepatic or lymph node metastasis, or other malignant tumors
  • Age between 18 and 80 years old
Not Eligible

You will not qualify if you...

  • Not meeting any of the inclusion criteria
  • Unwilling or unable to participate in follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chinese PLA General Hospital

Beijing, Beijing Municipality, China, 100853

Actively Recruiting

Loading map...

Research Team

C

Chuan Pang

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here